These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
321 related articles for article (PubMed ID: 24292870)
21. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. ; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728 [TBL] [Abstract][Full Text] [Related]
22. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients. Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622 [TBL] [Abstract][Full Text] [Related]
23. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer. Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419 [TBL] [Abstract][Full Text] [Related]
24. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry. Meng H; Chen R; Li W; Xu L; Xu L Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507 [TBL] [Abstract][Full Text] [Related]
25. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer. Chen JR; Chien HP; Chen KS; Hwang CC; Chen HY; Yeh KY; Hsieh TY; Chang LC; Hsu YC; Lu RJ; Hua CC Medicine (Baltimore); 2017 Jan; 96(2):e5582. PubMed ID: 28079792 [TBL] [Abstract][Full Text] [Related]
26. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. Press MF; Sauter G; Buyse M; Bernstein L; Guzman R; Santiago A; Villalobos IE; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Bee V; Taupin H; Flom KJ; Tabah-Fisch I; Pauletti G; Lindsay MA; Riva A; Slamon DJ J Clin Oncol; 2011 Mar; 29(7):859-67. PubMed ID: 21189395 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH). Kato N; Itoh H; Serizawa A; Hatanaka Y; Umemura S; Osamura RY Pathol Int; 2010 Jul; 60(7):510-5. PubMed ID: 20594272 [TBL] [Abstract][Full Text] [Related]
28. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. Hannemann J; Kristel P; van Tinteren H; Bontenbal M; van Hoesel QG; Smit WM; Nooij MA; Voest EE; van der Wall E; Hupperets P; de Vries EG; Rodenhuis S; van de Vijver MJ Br J Cancer; 2006 Nov; 95(10):1334-41. PubMed ID: 17088909 [TBL] [Abstract][Full Text] [Related]
29. Copy number analysis of c-erb-B2 (HER-2/neu) and topoisomerase IIalpha genes in breast carcinoma by quantitative real-time polymerase chain reaction using hybridization probes and fluorescence in situ hybridization. Murthy SK; Magliocco AM; Demetrick DJ Arch Pathol Lab Med; 2005 Jan; 129(1):39-46. PubMed ID: 15628907 [TBL] [Abstract][Full Text] [Related]
30. Visualization of FISH Probes by dual-color chromogenic in situ hybridization. Hoff K; Jørgensen JT; Müller S; Røngaard E; Rasmussen O; Schønau A Am J Clin Pathol; 2010 Feb; 133(2):205-11. PubMed ID: 20093229 [TBL] [Abstract][Full Text] [Related]
31. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496 [TBL] [Abstract][Full Text] [Related]
32. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer. Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383 [TBL] [Abstract][Full Text] [Related]
33. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)]. Akhdar A; Bronsard M; Lemieux R; Geha S Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120 [TBL] [Abstract][Full Text] [Related]
34. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas]. Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384 [TBL] [Abstract][Full Text] [Related]
35. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431 [TBL] [Abstract][Full Text] [Related]
36. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715 [TBL] [Abstract][Full Text] [Related]
37. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Zhao J; Wu R; Au A; Marquez A; Yu Y; Shi Z Mod Pathol; 2002 Jun; 15(6):657-65. PubMed ID: 12065780 [TBL] [Abstract][Full Text] [Related]
38. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. Tubbs R; Barlow WE; Budd GT; Swain E; Porter P; Gown A; Yeh IT; Sledge G; Shapiro C; Ingle J; Haskell C; Albain KS; Livingston R; Hayes DF J Clin Oncol; 2009 Aug; 27(24):3881-6. PubMed ID: 19620488 [TBL] [Abstract][Full Text] [Related]
39. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Arriola E; Marchio C; Tan DS; Drury SC; Lambros MB; Natrajan R; Rodriguez-Pinilla SM; Mackay A; Tamber N; Fenwick K; Jones C; Dowsett M; Ashworth A; Reis-Filho JS Lab Invest; 2008 May; 88(5):491-503. PubMed ID: 18332872 [TBL] [Abstract][Full Text] [Related]
40. Simultaneous detection of TOP2A and HER2 gene amplification by multiplex ligation-dependent probe amplification in breast cancer. Moelans CB; de Weger RA; van Blokland MT; van der Wall E; van Diest PJ Mod Pathol; 2010 Jan; 23(1):62-70. PubMed ID: 19767729 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]